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B22 Osteosarcoma Subtypes in Osteosarcoma Patients with 
Multiple Primary Malignancies. Can Rare Subtypes be 
Indicative for Cancer Syndromes Related with 
Osteosarcoma?
E.I. Hauben1, J.J. Arends2, J.P. Vandenbroucke2,
C. van Asperen2, E. van Marck3, P.C.W. Hogendoorn2
1Stichting PAMM, Eindhoven, The Netherlands, 2Leiden University 
Medical Center, Leiden, The Netherlands,
3Universitair Ziekenhuis, Antwerpen, Belgium
Although the overall incidence of osteosarcoma is low the occur-
rence of osteosarcoma in a setting of multiple primary tumours is
not  infrequent.  Association  between  osteosarcoma  and  other
malignancies is frequently the result of treatment, but can also be
the result of genetic predisposition. The aim of our study is to
establish  the  incidence  of  osteosarcoma  associated  with  other
malignancy in the Dutch population and to find out if rare osteosa-
rcoma  subtypes  occur  in  higher  frequency  in  patients  with
secondary malignancies and who are suspected to have a genetic
predisposition to malignancy.
Methods: Of all patients with the diagnosis of osteosarcoma regis-
tered  between  1975  and  May  2000  in  the  Dutch  National
Pathology Register, all patients were selected who had an other
malignancy before or after their diagnosis of osteosarcoma. In a
second step only those patients were retained for further study that
had a history of retinoblastoma or a history of malignancy before
the  age  of  45.  Of  these  patients  the  histological  material  was
reviewed and osteosarcomas were subtyped as common, chond-
roblastic, fibroblastic, anaplastic, telangiectatic, osteoclast rich or
small cell. As a control 570 patients entered in the database of the
European Osteosarcoma Intergroup were used.
Results: In total 1145 patients had a diagnosis of osteosarcoma, 65
had a history of multiple primary tumours. 7 of these patients were
rejected for further analysis, 2 were retinoblastoma patients and 22
had their malignancies before the age of 45. 47% of these patients
had an osteosarcoma subtype other than common as opposed to
29% in the control group. If only those patients were selected in
which  there  was  no  relation  with  treatment  and  second
malignancy, 90% had subtypes other than common. 
Conclusion:   a  non-common  subtype  of  osteosarcoma  may  be
predictive  for  a  patient  to  be  a  member  of a  cancer syndrome
family.
B23 Gene and Protein Expression Profiling in Fibroblasts 
Carrying a Li-Fraumeni p53 Germline Mutation that 
Induces Chemoresistence to Doxorubicin
L. Sangiorgi1, M.A. Cerone2, S. Soddu2, G.A. Gobbi1,
E. Lucarelli1, F. Scrimieri1, V. Maini1, A. Brach del Prever3,
P. Picci1, L.J. Helman4
1Istituti Ortopedici Rizzoli, BOLOGNA, Italy, 2Regina Elena Cancer 
Institute, Rome, Italy, 3University of Turin, Turin, Italy, 4NCI, NIH, 
Bethesda, MD, USA
Objective of the study: The study of gene expression profiling (with
cDNA  microarrays)  and  protein  expression  (by  co-immuno
precipitation)  help  in  the  identification  of  candidate genes  and
proteins involved in oncogenic pathways in the search of novel
therapeutic targets. 
Methods:  In  a  phenotypic  Li-Fraumeni  family,  a  germline  p53
mutations  at  codon 220  (amino  acid  change  from  tyrosine  to
serine) was identified. We generated by site directed mutagenesis
a plasmid encoding the p53SER220 mutation (pLp53-S220) and
transfected fibroblasts from p53 -/- mice (F10) with this vector.
Drug sensitivity (assessed by IC50 value) of the fibroblasts carrying
the  mutation  was  evaluated  for  doxorubicin,  cisplatin  and  5-
florouracil. Fibroblasts carrying the p53SER220 mutation showed
a selective resistance for doxorubicin. We treated with doxorubicin
the p53SER22, p53 wild type and p53 -/- fibroblasts and we eval-
uated the gene expression profiles of these cells at different time
points. Moreover, we performed a co-immuno precipitation with a
p53 antibody in cellular lysate of p53 wild type and p53SER220
fibroblasts also treated with doxorubicin to evaluate the protein
expression profiles at different time points. 
Results: Distinct patterns of gene expression for the three different
fibroblasts were identified. Additionally, lists of doxo-dependent
and doxo-independent activated genes were determined. Analysis
of these gene lists pinpoint a number of signal transduction and cell
cycle  genes  differentially  expressed.  Co-immuno  precipitation
experiments resulted in the presence of additional bands 24 h after
doxorubicin  treatment  when  the  p53SER220  fibroblasts  were
compared with the wild-type cells and these bands could identify
proteins involved in the chemoresistance. 
Conclusion:  Several genes and protein are expressed according to
the different p53 status after doxorubicin treatment. These studies
may evolve in development of novel therapeutic strategies. 
B24 Somatic and Germinal Alteration of the TP53 Gene in 
Pediatric Osteosarcoma
A. Patiño, E. 1 Sotillo, M. Zalacain, L. Gárate, M. San-Julian,
E. Noain, L. Sierrasesumaga
University Clinic of Navarra, Pamplona, Spain
Paediatric osteosarcoma (OS) is a puzzle of genetic alterations in
genes involved in the arrest of the cell cycle in response to DNA
damage. Alteration of the TP53 gene has been detected in sporadic
and in hereditary OS in the context of the Li-Fraumeni Syndrome. 
Objective: To analyse the alteration of the TP53 gene in Spanish
paediatric OS both at the germinal and somatic levels. 
Methods: Blood samples were obtained from 76 OS (42 males/34
females, median age at diagnosis 13.13±3.16 years), 136 healthy
volunteers  and  paired  tissues  were  available  from  41  of  the
patients.  Loss  of  heterozygosity  was  tested  by  the  analysis  of
P53IVS1, and mutation by PCR-DGGE and sequencing. 
Results: TP53 alteration was detected in 42.9% of the tissues and
in 5.3% of blood samples (Table I). Mutations were nucleotide
changes  except  two  cases  with  frameshift  mutations.  Table  I.
Features of the OS patients with TP53 germline mutations. TP53
mutation Necrosis/subtype Survival/*EFS Other findings 
#1Codon 250  (CCC-TTC) 20%/Chondroblastic  54/0  Died  of
secondary ALL 
#2Codon 223 (G deletion) 80%/Osteoblastic145/145 Long term
remission 
#3Codon 196  (CGA-TGA)  90%/Chondroblastic  84/0  Died  of
disease.  Mother  and  grandfather  died  of  leukaemia  and  colon
respectively 
#4Codon  132  (AAG-AAC)  40%/Chondroblastic11/-Still  in
treatment 
*EFS: Event-free survival in months. 
The median age at diagnosis of patients with mutated TP53 (15.8
years) was statistically higher (p=0.038) than that of patients with
normal TP53 (12.8 years). 
Conclusion:  Alterations of TP53 are present in about half of OS
tumour samples, confirming the outstanding role of this gene in
tumourigenesis.  Four  of  our patients  were  germline  carriers  of
TP53 alterations, while none of the healthy controls had TP53
mutation. The difference in the age  at diagnosis depending onS14 EMSOS abstracts
TP53 mutation status has also been detected by other authors,
reflecting  the  existence of different  subsets  of OS  patients  that
should be further investigated. 
B25 Chromosome 9 Alterations and p16 Expression in 
Central Chondrosarcomas
H.M. van Beerendonk1, L.B. Rozeman1, A-M. Cleton-Jansen1,
R. Sciot2, A.H.M. Taminiau3, J.V.M.G. Bovée1, P.C.W. 
Hogendoorn1
1Dept. of Pathology, Leiden University Medical Center, Leiden, The 
Netherlands,  2Dept. of Pathology, Leuven University, Leuven, 
Belgium, 3Dept. of Orthopaedic Surgery, Leiden University Medical 
Center, Leiden, The Netherlands
Introduction:   Chondrosarcomas  are  characterised  by  neoplastic
growth  of  cartilage  forming  tumour  cells.  The  majority (75%)
arises centrally, in the medullar cavity, while a minority develops
peripherally  secondary  to  an  osteochondroma.  We  previously
investigated DNA-ploidy and loss of heterozygosity (LOH) at loci
harbouring  the  EXT-genes  (implicated  in  hereditary  multiple
exostoses), the EXT-like genes, and at 9p21, 13q14, 17p13 and
chromosome  10  in  12  central  chondrosarcomas.  Only  3  cases
exhibited LOH, with 9p21 involved in all three. At 9p21 the p16
tumour suppressor  gene is  located. Previous studies  showed in
seven central chondrosarcomas an abnormal karyotype, 5 of which
involved chromosome 9. Questions are the cell  cycle  inhibitors
CDKN2A/p16  or  CDKN2B/p19,  located at  9p21,  involved  in
chondrosarcoma tumourigenesis? 
Methods: p16 immunohistochemistry was performed on formalin-
fixed paraffin-embedded tissue of 60 cases of central chondrosar-
coma to estimate  the effect of 9p21  alterations on p16  protein
expression. Loss of heterozygosity (LOH) analysis was performed
in the region of p16 on 52 central chondrosarcomas. SSCP anal-
ysis was done on 48 cases for p16 and p19. Methylation of the p16
gene promoter was studied by methylation specific PCR (MSP).
Results: The involvement of genes located at chromosome 9, espe-
cially the 9p12–22 region, is suggested both by LOH, p16 immu-
nohistochemistry and cytogenetic studies. Loss of expression of the
p16 protein was found in 19.7% of the cases. LOH was found on
9p in 47% of the informative cases. SSCP analysis did not reveal
mutations in the p16 or p19 genes in any of the tumours. MSP
analysis  showed that  in  some  tumours  methylation  of  the  p16
promoter  occurs  when  p16  protein  expression  is  absent  or
decreased.
Conclusion:  our  results  show  that  inactivation  of  p16  protein
expression occurs in central chondrosarcoma and may be caused
by LOH and promoter methylation. 
B26 Identification and Clinical Validation of Candidate 
Target Genes from the Amplified Region on Chromosome 
Arm 17Q in Malignant Peripheral Nerve Sheath Tumours
S. Smeland1, R.I. Skotheim1, O. Monni2, J.M. Nesland1,
B. Bjerkhagen1, A.E. Stenwig1, F. Mertens3, O-P. Kallioniemi4, 
A. Kallioniemi4, R.A. Lothe1
1The Norwegian Radium Hospital, OSLO, Norway, 2Biomedicum 
Helsinki, Helsinki, Finland, 3University Hospital, Lund, Sweden, 
4NHGRI, National Institutes of Health, Bethesda, USA
Patients with neurofibromatosis type I are predisposed to acquire
malignant tumours, including malignant peripheral nerve sheath
tumours  (MPNSTs).  By  genome  wide  DNA  copy  number
analyses by comparative genomic hybridisation (CGH) we discov-
ered that most MPNSTs have extra copies of the distal part of the
long  arm  on  chromosome  17  (Lothe  et  al.,  Cancer  Res.
56(20):4778–81 1996). Others have later confirmed this finding.
In order to identify the overexpressed target gene(s) responsible for
the selective advantage of this genomic amplification in tumours,
we submitted a series of 14 MPNSTs to a detailed gene expression
profiling focused on chromosome 17. The custom made chromo-
some 17-specific  cDNA microarrays contained 636  transcribed
sequences,  including  all  known  genes  as  well  as  hundreds  of
expressed sequence tags from chromosome arm 17q. This led us
to  the  identification of  several differentially-  and overexpressed
genes, some of which we consider as candidates for driving the
genomic  amplification.  The  five  mostly  overexpressed  genes/
transcripts  on  chromosome  arm  17q  were  AP2B1,  GCN5L2,
TIMP2, TOP2A, and an expressed sequence tag (Image clone ID
1097923). Candidate genes are currently under clinical validation
in  a cohort  of  41  patients  admitted  to the Norwegian Radium
Hospital the past 20 years. Protein expressions are evaluated by
immunohistochemistry on a tissue microarray made from qualified
tumour areas from the archival blocks.
B27 Association Between the Occurrence of Breast Cancer 
and Cartilaginous Tumours: Phenotypic Characterization 
of a Hitherto Unrecognized Potential Hereditary Trait
A.M.Cleton-Jansen, M. Timmerman, I. Briaire-de Bruijn, M. van 
de Vijver, C. van Asperen, L.C.J.M. van den Broek, H.M. Kroon, 
P.C.W. Hogendoorn
Leiden University Medical Center, Leiden, The Netherlands
Introduction:   Recently  we  documented  a  strong  association
between the occurrence of cartilaginous tumours (enchondroma,
chondrosarcoma) and breast cancer in the same patient, using a
nation-wide case-control study. This study revealed an odds ratio
of  7.62  for  a  potential  association  of  breast  and  cartilaginous
tumours, pointing statistically strongly towards a genetic trait. This
is furthermore corroborated by the age of onset in patients with
breast cancer as the first tumour, which is about 10 years earlier
than breast cancer in the general population. 
Objective: We have investigated clinical and phenotypic properties
of the breast- and the cartilaginous tumours in patients with both
tumour types to identify a possible characteristic spectrum for this
hereditary trait. 
Methods: Using the national pathology database the tissue blocks of
all patients  reported to fulfil the associated tumours mentioned
were retrieved. Reported diagnoses were reviewed; breast cancer
specimens  were  classified  and  histologically.  In  addition  the
cartilaginous tumours were analysed with emphasis on the central
versus peripheral localisation in the skeleton as previous studies
proved a different molecular mechanism to be operative in the
different subtypes. Expression of p53, Bcl2, Her2-neu, p16, p21
oestrogen  and  progesterone  receptor  and  E-cadherin  was
determined by immunohistochemistry. 
Results and Conclusion: No case of chondrosarcoma nor enchon-
droma was reported in the Dutch BRCA1 and BRCA2 database,
pointing  to  a  trait  which  is  different  from  the  aforementioned
breast cancer syndromes. Remarkably all  cartilaginous tumours
are of one common histological subtype being centrally localised
whereas  no  peripheral  cartilaginous  tumour  was  registered.
Furthermore  the  cartilaginous  tumours  showed  a  significantly
higher p16 and p21 staining. The breast tumours were histologi-
cally heterogeneous with varying differentiation grade. Character-
istics  of the breast cancers: 10 years earlier age of onset, higher
mitotic count, less lymph infiltrate, high ER staining and high p53
staining.EMSOS abstracts S15
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B28 Aneurysmal Bone Cyst: A Heriditary Disease?
A.L. Leithner1, F. Machecek Jr.2, O.A. Haas3, S. Lang4,
P. Ritschl2, R. Kotz4, R. Windhager1
1Karl Franzens University, Graz, Austria, 2Orthopedic Hospital 
Gersthof, Vienna, Austria, 3St. Anna Children’s Hospital, Vienna, 
Austria, 4Vienna University Hospital, Vienna, Austria
Object of study: Recent genetic and immunohistochemical studies
propose that primary aneurysmal bone cyst is a tumour and not a
reactive  tumour-simulating  lesion.  Furthermore,  chromosomal
analysis  and five  reported familial  cases  of  this  osteolytic  bone
lesion propose a hereditary factor in a presumably multifactorial
pathogenesis. 
Methods: The authors contacted 133 patients with this disease. 66
females  and 66  males  (median age 14  years; range 2–66) were
asked if they knew of the occurrence of bone lesions at other family
members. If the answer was positive, histology, radiology, and the
patient’s history were reviewed. 
Results: 103 patients (77%) denied, 25 patients (19%) were lost to
follow up, and 5 patients (4%) gave evidence for other bone lesions
in the family – two patients were father and son (this case has been
reported in 1998), another patient knew of a giant cell tumour G1
of an uncle’s distal  tibia, the father of a further patient had an
asymptomatic small cystic defect in the right proximal femur, and
another patient knew that  forty years ago her father underwent
surgery for a cystic lesion of the palate. 
Conclusion:  These data indicate that a predisposing genetic defect
could be part of a multifactorial pathogenesis of aneurysmal bone
cyst. Furthermore, the coincidence of an aneurysmal bone cyst
and  a  giant  cell  tumour  in  one  family  rises  questions  for  a
stronger context between those two, sometimes strikingly similar
lesion. 
B29 Expression Profiling of Osteosarcoma Biopsies and 
Metastases with cDNA Microarrays
L. Sangiorgi1, G.A. Gobbi1, E. Lucarelli1, F. Scrimieri1,
V. Maini1, P. Picci1, L.J. Helman2
1Istituti Ortopedici Rizzoli, Bologna, Italy, 2NCI, NIH, Bethesda, 
MD, USA
Objective of the study: Expression profiling with cDNA microarrays
offers the possibility to determine global patterns of gene expres-
sion tumour specimens which can be used for diagnostic classifica-
tion,  the  identification  of  subsets  as  well  as  the  elucidation  of
oncogenic pathways and novel therapeutic targets. 
Methods: We have explored  the potential of  applying this  tech-
nology to osteogenic sarcoma. 14 primary osteosarcomas and 8
osteosarcoma pulmonary metastases were analysed by hybridisa-
tion to cDNA microarrays. For comparison, five Ewing’s sarcoma
specimens, and normal lung tissue were also analysed. 
Results: We determined that high quality results could be obtained
from osteosarcoma specimens despite the presence of extracellular
matrix  material  in  these  specimens.  A  distinct  pattern  of  gene
expression for osteosarcoma was readily identified. This osteosar-
coma specific gene expression signature was detectable in pulmo-
nary metastases. Additionally, lists  of genes, which discriminate
osteosarcoma and Ewing’s sarcoma, were developed. Inspection of
these gene lists identifies a number of signal transduction and cell
cycle genes utilised differentially by these two cancers. 
Conclusion:  Several genes expressed by osteosarcoma have poten-
tial for development as targets for immunohistochemical detection
for diagnostic purposes. 
B30 High Quality RNA Isolation from Tumours with Low 
Cellularity and High Extracellular Matrix
J.J. Baelde1, A-M. Cleton-Jansen1, H.M. van Beerendonk1,
M. Namba2, J.V.M.G. Bovée1, P.C.W. Hogendoorn1
1Dept Pathology, Leiden University Medical Center, Leiden, The 
Netherlands,  2Dept. of Cell Biology, Institute of Molecular and Cellular 
Biology, Okayama University Medical School, Shikata, Japan.
Introduction:  High quality RNA isolation from cartilaginous tissue
is considered difficult due to relative low cellularity and the abun-
dance  of  extracellular  matrix  rich  in  glycosaminoglycans  and
collagen. Given the growing interest and technical possibilities to
study RNA expression at a high throughput level research on tissue
bearing these characteristics is therefore hampered. 
Methods:  We  present  a  robust  protocol  combining  two  RNA
isolation procedures based on a combination of trizol and RNA
specific columns that has been developed to obtain high molec-
ular weight RNA from fresh frozen and stored tissue of normal
cartilage  and  cartilaginous  tumours.  Using  this  method  RNA
was  isolated  from  normal  cartilage,  peripheral  and  central
chondrosarcoma. 
Results: RNA per mg tissue. RNA isolated with this method was
stable and of high molecular weight. RNA samples from normal
cartilage  and  from  two  chondrosarcomas  isolated  using  this
method  were  applied  successfully  in  cDNA  microarray experi-
ments; The yields ranged from 0.1–0.5 The number of genes that
give interpretable results was in the range of what is expected when
compared with microarray results  obtained on chondrosarcoma
cell line RNA. Signal-to-noise ratios were good and differential
expression between tumour and normal cartilage was detectable
for a large number of genes. 
Conclusion:   With  this  newly  developed  isolation  method  high
quality RNA can be obtained from low cellular tissue with high
extracellular matrix component. These procedures can be applied
to other tumour material as well. 
B31 Role of the MET/HGF Receptor in Proliferation and 
Invasive Behaviour of Osteosarcoma
R Ferracini1, N Coltella1, MF Di Renzo1, C Manara2,
L Trusolino1, K Scotlandi2
1IRCC, Candiolo (Torino), Italy, 2Istituti Ortopedici Rizzoli, Bologna, 
Italy
The hepatocyte growth factor (HGF/SF) receptor Met regulates
mitogenesis, motility and morphogenesis in a cell type-dependent
fashion. The signal transduction pathway activated by Met after
binding of HGF and dimerization of the receptor involves trans-
phosphorylation of the intracellular domain of Met and leads to the
activation  of  multiple  pathways  accounting  for  the  complex
invasive growth response. 
Methods: We analysed the effect of the aberrantly expressed Met
receptor gene in osteosarcoma cell lines characterising the down-
stream-activated  pathways  and phenotypic changes  induced by
Met activation. Five cell lines derived from human osteosarcomas
were tested: U-2OS, MG-63, Saos-2, IOR/OS9 and IOR/OS10.
We  evaluated  the  levels  of  MAPK  and  PKB/Akt  activation
following stimulation with HGF by Western blot analysis. For cell
growth assay, cells were starved in medium devoid of serum and
growth factors for 48 h, detached and plated in 24-well plates in a
serum-free medium supplemented with different concentration of
HGF for 48 hours. Cell number was estimated after staining with
Crystal  Violet  by  a  colorimetric  assay.  A  motility  assay
was performed evaluating  the  migration  of  the  cells  through  a
polycarbonate filter (Transwell). S16 EMSOS abstracts
Results: All the cell lines tested expressed high levels of the MET
proto-oncogene and two of them  (MG-63  and IOR/OS10) co-
expressed HGF. Four cell lines (U-2OS, Saos-2, IOR/OS9 and
IOR/OS10)  showed  the  activation  of  the  MAPK  cascade
suggesting a common proliferative role of the HGF. Two lines (U-
2OS, Saos-2) showed activation of PKB/Akt, which is known to be
involved in migration mediated by HGF receptor. These data are
confirmed by proliferation and motility assay in vitro. 
Conclusion:  These  data  suggest  that  HGF  activates  both  the
mitogen and motogen machinery in osteosarcoma cells, promoting
the malignant behaviour of these cells at different steps. Inhibition
of  the  paracrine/autocrine  HGF/Met  circuit  may  represent  a
promising target for innovative therapies in osteosarcoma.
B32 Telomerase Activity and Telomere Length in Pediatric 
Bone Tumours
E. Sotillo, M. San-Julian, E. Noain, L. Sierrasesúmaga, A. Patiño
University Clinic of Navarra, Pamplona, Spain
Telomeres are structures at the end of eukaryotic chromosomes that
are shortened with each cellular division. Telomerase is the ribo-
nucleoprotein that adds telomeric DNA compensating for telomere
loss, and is expressed in about 85–90% of all tumour types. Bone
tumours account for 7% of all childhood malignancies in Spain: 4%
are osteosarcomas (OS) and 3% Ewing’s sarcomas (ES). 
Objective: To analyse the presence of telomerase activity (TA) and
the TRF length (Telomeric Restriction Fragments) in primary and
metastatic tissues from Spanish paediatric OS and ES patients. 
Methods: TA was determined by TRAP (Telomeric Repeat Ampli-
fication Protocol) analysis in tumour tissue samples obtained from
OS (9 primary tumours, 8 metastases) and ES patients (8 primary
tumours,  5  metastases).  The  TRF  length  was  measured  by
Southern Blot in the same tissue samples. 
Results: Telomerase Activity (TA) was detected in 84.5% (11/13)
of  the  metastatic  tissues  and  in  11.7%  (2/17)  of  the  primary
tumours (p<0.001) (Table I). 
Table I. Telomerase activity in bone tumour tissues. 
Sample typeNumber analysed/Number with TA + 
OS Primary tumour 9/1 
Metastases 8/6 
ES Primary tumour 8/1 
Metastases 5/5 
Bone Tumours Primary tumour 2/17 
Metastases 11/13 
The mean TRF length of samples that lacked telomerase activity
(11.6 Kb) was statistically longer (p=0.041) than that of samples
with detectable telomerase activity (8.7 Kb). 
Conclusion: TA is not responsible for the telomeric maintenance in
the initial steps of the carcinogenesis of paediatric bone tumours,
but is  essential  for achieving the full malignant  phenotype and
metastatic capacity. Primary bone tumours must use any Alterna-
tive  Lengthening  Telomere  mechanisms,  which  are  related  to
longer TRFs. A possible hypothesis is that a scarce numbers of
tumoural  cells  that  posses  telomerase  activity  are  those  that
generate the metastatic nodules. 
B33 Protease Inhibitors as Prognostic Factors in High Risk 
Soft Tissue Sarcomas (STS)
M.S. Beans, G. Magagnoli, F. Ponticelli, L. Pazzaglia,
G. Gamberi, P. Ragazzini, P. Picci
Istituti Ortopedici Rizzoli, Bologna, Italy
Matrix metalloproteinases (MMPs) degrade components of  the
extracellular matrix and are implicated in tissue remodelling and
tumour  infiltration.  Tissue  inhibitors  of  metalloproteinases
(TIMPs) inhibit enzymes of the MMP family and preserve stromal
integrity, thus inhibiting tumour migration. An unbalance in this
proteolytic  activity  may  contribute  to  tumour invasiveness  and
metastasis.  The  present  study  evaluated  MMP2  and  -9  tissue
enzymatic activity as well as the expression and serum level of their
inhibitors TIMP1 and -2, in selected patients with high risk STS,
to evaluate the alterations of proteolytic cascade in malignancy
progression. 
Methods: The level and distribution of MMP2, MMP9, TIMP1
and TIMP2 expression were evaluated in 69 biopsies of primary
STS including: 15 high grade liposarcomas, 19 synovial sarcomas,
7 high grade MPNST and 28 high grade MFH. The study was
carried out by immunohistochemistry and zymography. To test
plasma  TIMP1  and  -2  concentration,  blood  samples  were
collected from 53  patients before treatment and measured with
enzyme-linked  immunoabsorbent  assay  (ELISA).  Histological
types  included  20  liposarcomas,  13  synovial  sarcomas  and  20
MFH. 58 healthy subjects were included as control group. 
Results: By zymography analysis, 52% and 49% of the 69 tumours
had  significant  enzymatic  activity  of  MMP2  and  MMP9
respectively. TIMP2 expression was inversely correlated to poor
prognosis  in  terms  of  disease  free  survival and  overall  survival
(p<0,003, p<0,006  respectively). In the metastatic  group, 78%
patients lacked TIMP2 expression versus 43% in the disease free
patients.  Plasma  concentration  of  TIMP1  and  -2  in  53  STS
patients revealed significantly lower levels compared to controls. 
Conclusion:  The Results of this study showed that TIMP1 and -2
are involved in the progression of high grade STS. 
B34 Primary Malignant Tumours of Bone Following 
Previous Malignancy
J.T. Patton, S. Sommerville, R. Grimer
Royal Orthopaedic Hospital, Birmingham, United Kingdom
The purpose of this study is to emphasise the necessity for caution
in assuming the diagnosis of a metastasis  when a solitary bone
lesion  is  identified  following  a  prior  malignancy.  Bone  lesions
occurring in patients who have previously had a malignancy are
generally assumed to be a metastasis from that malignancy. We
reviewed 60 patients with a previous history of malignancy, who
presented with a bone lesion that was subsequently found to be a
different primary  sarcoma of bone. These  second malignancies
occurred in three distinct groups of patients. 
1. Patients with original tumours well known to be associated with
second malignancies (5%) 
2. In patients whose second malignancies were likely to be due to
the previous treatment of their primary malignancy (40%) 
3. In patients in whom there was no clearly defined association
between malignancies (55%) 
Inappropriate  biopsy  and  treatment  of  primary  bone  sarcomas
compromises limb salvage surgery and can affect patient mortality.
We would advise referral of any aggressive solitary bone lesion to a
regional bone tumour service for further assessment and biopsy
rather than to assume the lesion is a metastasis. 
B35 Protease Inhibitors as Prognostic Factors in High Risk 
Soft Tissue Sarcomas (STS)
A. Balladelli, M.S. Benassi, G. Magagnoli, F. Ponticelli,
L. Pazzaglia, G. Gamberi, P. Ragazzini, P. Picci
Istituti Ortopedici Rizzoli, Bologna, Italy
Matrix metalloproteinases (MMPs) degrade components of the
extracellular matrix and are implicated in tissue remodelling andEMSOS abstracts S17
tumour  infiltration.  Tissue  inhibitors  of  metalloproteinases
(TIMPs) inhibit enzymes of the MMP family and preserve stromal
integrity, thus inhibiting tumour migration. An unbalance in this
proteolytic  activity  may  contribute  to  tumour  invasiveness  and
metastasis. The present study evaluated MMP2 and -9 tissue enzy-
matic activity as well as the expression and serum level of their
inhibitors TIMP1 and -2, in selected patients with high risk STS,
to evaluate the alterations of  proteolytic  cascade in malignancy
progression. The level and distribution of MMP2, MMP9, TIMP1
and TIMP2 expression were evaluated in 69 biopsies of primary
STS including: 15 high grade liposarcomas, 19 synovial sarcomas,
7 high grade MPNST and 28 high grade MFH. The study was
carried out by immunohistochemistry and zymography. To test
plasma  TIMP1  and  -2  concentration,  blood  samples  were
collected from 53 patients before treatment and measured with
enzyme-linked  immunoabsorbent  assay  (ELISA).  Histological
types  included  20  liposarcomas,  13  synovial  sarcomas  and  20
MFH. 58  healthy  subjects  were included as  control group. By
zymography analysis, 52% and 49% of the 69 tumours had signif-
icant  enzymatic  activity  of  MMP2  and  MMP9  respectively.
TIMP2 expression was inversely correlated to poor prognosis in
terms  of  disease  free  survival  and  overall  survival  (p<0,003,
p<0,006  respectively).  In  the  metastatic  group,  78%  patients
lacked TIMP2 expression versus 43% in the disease free patients.
Plasma  concentration  of  TIMP1  and  -2  in  53  STS  patients
revealed significantly lower levels compared to controls. 
Conclusion:  The Results of this study showed that TIMP1 and -2
are involved in the progression of high grade STS. 
B36 Using Spectral Karyotyping and Array-Based
CGH to Detect Specific Genomic Amplification in 
Rhabdomyosarcoma
Y. Kollender1, M. Goldstein2, A. Bar-Shira2, H. Rennert2,
R. Shomrat2, J. Issakov3, A. Orr-Urtreger2, I. Meller1
1Nat. Unit of Orthopedic Oncology, 2The Genetics Institute and 
3Pathology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, 
Israel 
Rhabdomyosarcoma  (RMS)  is  histologically  divided  into  two
main subtypes: embryonal (ERMS) and alveolar (ARMS), each
associated with different genetic changes. ARMS is characterized
by the fusion of FKHR at 13q14 with either PAX3 at 2q35, or,
less commonly, with PAX7 at 1p36, while no consistent chromo-
somal  abnormalities  are  observed in  ERMS. To identify  novel
genetic  changes  associated  with  RMS,  cytogenetic  and  array-
based  comparative  genomic  hybridisation  (array-based  CGH)
analyses were employed on eight pathologically-diagnosed RMS
tumours. Of the 3 ERMS specimens examined, 2 demonstrated a
normal karyotype, while  the  third  sample  displayed changes in
several chromosome including 2, 7 and 8. In ARMS, structural
rearrangements  were  detected  in  4  of  the  5  tumours  tested.
Involvement of 13q14 region was detected in 3 cases, but only one
case showed a characteristic t(2;13), in addition to other aberra-
tions.  The  other  2  cases  displayed  ins(13;13)  (q14;q1?)  in  a
complex karyotype, and a t(13;20) (q14;q13.3), in addition to a
large number of double minutes (dmins), respectively. Spectral
karyotyping analysis identified the dmins origin as chromosome
13, while the dmins detected in the last tumour as a sole cytoge-
netic aberration, were classified as derived from chromosome 1.
Array-based CGH analysis of 57  genes commonly amplified  in
cancer, detected a single co-amplification of GLI (2.5-fold) and
SAS/CDK4  (3.2-fold)  in  the  ARMS  specimen  harbouring  the
t(13;20) and dmins(13). 
Conclusion:  This data demonstrates that using a combination of
advanced molecular and cytogenetic techniques, namely SKY and
array-based CGH, allowed us to better characterize some of the
genetic changes which may contribute to RMS tumourigenesis, in
particular, the dmins and gene amplification events. 
B37 Molecular Karyotyping Approach for the
Characterisation of Soft Tissue Tumours.
K. Szuhai, M. Yszenga, J. Knijnenburg, H.J. Tanke, P.C.W. 
Hogendoorn, C. Rosenberg
Leiden University Medical Center, Leiden, The Netherlands
Soft tissue tumours constitute a heterogeneous and complex group
of  mesenchymal  lesions.  Chromosomal  analysis  and  molecular
cytogenetic approaches had a great impact on the classification and
diagnosis of these tumours. However, because of the lack of molec-
ular markers, it is still difficult to discern in a number of tumour
types  benign  lesions  from  malignant  ones  based  purely  on
histology. We set up a complex molecular approach to analyse new
cases by using a multicolour FISH (COBRA FISH) approach and
comparative  genomic  hybridisation  (CGH)  for  genome-wide
screening and determination of alteration of the tumour genome.
Multifluorescent in  situ  hybridisation using whole chromosome
painting  probe  sets  may  help  to  pinpoint  recurrent aberration,
which would improve the (sub)classification of different entities.
Complex chromosomal rearrangements are further characterised
by hybridisation-based staining of pan-centomeric/telomeric and
subtelomeric sequences. Candidate regions are analysed by high-
resolution BAC/PAC hybridisations on small or large-scale arrays
to determine new genes involved in the disease. The detected rear-
rangements are confirmed on archived materials by using FISH or
PCR based approaches. So far we have analysed more than 40 new
cases of various tumour types and the approach is illustrated with
representative cases. 
B38 Growth Hormone Gene Expression in Canine 
Osteosarcoma
J. Kirpensteijn, E. van Garderen, E.P.M. Timmermans-Sprang, 
G.R. Rutteman, J.A. Mol
Utrecht University, Utrecht, The Netherlands
Introduction:   Growth  hormone  (GH)  and  Insulin-like  growth
factor-I (IGF-I) play an important role in bone and osteosarcoma
(OS) formation. Local GH gene expression was present in 25% of
canine OS (1). The purpose of this study was to evaluate if other
important growth promoting factors are present in canine OS and
to  evaluate  if  local  GH  gene  expression  will  affect  disease
progression in canine OS. 
Methods: We screened 60 bone tumours for local gene expression
of GH, GH receptor (GHR), IGF-I, and insulin-like growth factor
binding  protein-5  (IGFBP-5),  and  venous  plasma  GH  level.
Multivariate Cox regression analysis was performed to evaluate if
the local expression of these factors may affect the clinical outcome
of dogs with OS. 
Results: Local expression of GH, GHR, IGF-I and IGFBP-5 genes
was demonstrated in canine OS. There was a significant difference
in expression of the GH gene, but not of the GHR, IGF-I and
IGFBP-5 gene between high and low-grade tumours. No signifi-
cant correlation was found between GH expression and expression
of any of the other genes or with the central venous plasma GH
level. Local expression of the GH gene was associated with a higher
hazard ratio for a decreased disease free interval and survival time
in dogs with OS. 
Conclusion:  This research substantiates earlier results that canine
OS express the GH gene on a local level. The local production of
GH most likely plays a role in the growth of neoplastic bone lesionsS18 EMSOS abstracts
through factors that are common in normal bone formation in the
dog, and has a negative effect on survival data.
B39 Telomere Length is Related to Survival in Pediatric 
Patients with Bone Tumours Undergoing Chemotherapy 
Treatments
E. Sotillo, M. San-Julian, E. Noain, L. Sierrasesúmaga, A. Patiño
University Clinic of Navarra, Pamplona, Spain
Telomeres are structures at the end of eukaryotic chromosomes
that  are shortened with each cellular division, being one of the
limiting  factors  for  cellular  proliferation.  Most  of  the  chemo-
therapy  treatments  are  designed  to  act  against  immortal  cells,
which have shorter telomeres due to their higher proliferative rates. 
Objective:  To  compare  the  TRF  (Telomeric  Restriction  Frag-
ments)  length  of  blood  samples  from  paediatric  osteosarcoma
(OS)  and  Ewing’s  sarcoma  (ES)  patients  before  and  after  the
chemotherapy treatments. 
Methods: Blood samples were obtained from 15  OS and 18  SE
patients at the beginning as well as after the chemotherapy cycles.
The TRF length was measured by Southern Blot. 
Results: TRF length at the beginning of treatment was statistically
shorter in patients  with survival periods >2 years, compared to
those patients who died within 2 years after diagnosis (p=0.032).
This difference was conserved when the survival period considered
was increased to 5 years (p=0.005). The TRF length of samples at
the beginning and at the end of treatment was statistically different
in patients with more than either 5 or 2 years of survival, opposite
to those patients who died within 2 years after completion of chem-
otherapy, whose telomeres had the same length at the beginning
and after treatment (Table I). 
Table I: Difference between the TRF length at the beginning and
after treatment in relationship to survival. 
Survival Number of samples, Difference in TRF length 
< 2 years 90.9 Kbp=0.041 
2–5 years 130.5 Kbp=0.046 
> 5 years 110.1 Kbp=0.563 
Conclusion: Bone tumour patients that have shorter TRFs lengths
at the beginning of chemotherapy have longer survival rates than
those patients with longer TRFs. The difference between the TRF
length at the beginning and at the end of treatment seems to be
related to survival in bone cancer paediatric patients undergoing
chemotherapy. 
B40 Multiple Primary Malignancies in Patients with Soft 
Tissue Sarcomas
O. Merimsky, J. Issakov, Y. Kollender, I. Schwartz, J. Bickels,
G. Flusser, M. Inbar, I. Meller
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Modern cancer treatment has substantially increased the survival
of patients with various malignancies. One of the late sequelae of a
successful treatment is  the  development of  a second malignant
tumour. However, in many cases of second primary cancers, expo-
sure to chemotherapy or radiation therapy is not evident, and it
should be postulated that the putative mechanism for the develop-
ment of the second-tumour is different. Retrospective search of
data files of 610 patients with soft-tissue or bone-sarcomas were
treated by our team of Musculoskeletal-Oncology from January
1995 through December 1999 was performed. Out of 375 patients
with STS, 28 (7.5%) developed other malignant neoplasms either
before or after its diagnosis. STS as the first tumour occurred in 14
patients.  The  second-tumour-types  included  mainly  STS  and
renal-cell-carcinoma. The interval of time between the diagnosis of
the  STS and the second malignancy was 0  to 21  years. Three
patients developed a third primary tumour within 0–3 years after
the diagnosis of the second tumour. The median overall survival
was >78 months. Fourteen patients had a first primary tumour
other  than  STS. The  second  tumours  (mainly  STS)  appeared
within 0 to 27 years . The median overall survival of the 14 patients
in this  group from the  diagnosis  of the first  tumour was  >102
months. An updated series will be presented. 
Conclusion:  The phenomenon of two or three primary neoplasms in
patients in whom one of the tumours was STS occurs in a rate of
7.5%  –  a  significantly  higher  rate  than  the  occurrence of  STS
among the  general cancer population (1%). Most  of  the  cases
occur incidentally. The clinical implications are the need to search
for an occult second primary in patients with STS, as an integral
part of their follow-up. It is especially true in patients with primary
MFH who show a risk for developing a renal-cell-carcinoma.